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Reduced Adipose Tissue Oxygenation in Human Obesity
Evidence for Rarefaction, Macrophage Chemotaxis, and
Inﬂammation Without an Angiogenic Response
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Laura E. Roan, Jennifer C. Rood, David H. Burk, and Steven R. Smith
OBJECTIVE—Based on rodent studies, we examined the hy-
pothesis that increased adipose tissue (AT) mass in obesity
without an adequate support of vascularization might lead to
hypoxia, macrophage inﬁltration, and inﬂammation.
RESEARCH DESIGN AND METHODS—Oxygen partial pres-
sure (AT pO2) and AT temperature in abdominal AT (9 lean and
12 overweight/obese men and women) was measured by direct
insertion of a polarographic Clark electrode. Body composition
was measured by dual-energy X-ray absorptiometry, and insulin
sensitivity was measured by hyperinsulinemic-euglycemic clamp.
Abdominal subcutaneous tissue was used for staining, quantita-
tive RT-PCR, and chemokine secretion assay.
RESULTS—AT pO2 was lower in overweight/obese subjects
than lean subjects (47  10.6 vs. 55  9.1 mmHg); however, this
level of pO2 did not activate the classic hypoxia targets (pyruvate
dehydrogenase kinase and vascular endothelial growth factor
[VEGF]). AT pO2 was negatively correlated with percent body fat
(R  0.50, P  0.05). Compared with lean subjects, overweight/
obese subjects had 44% lower capillary density and 58% lower
VEGF, suggesting AT rarefaction (capillary drop out). This might
be due to lower peroxisome proliferator–activated receptor 1
and higher collagen VI mRNA expression, which correlated with
AT pO2 (P  0.05). Of clinical importance, AT pO2 negatively
correlated with CD68 mRNA and macrophage inﬂammatory
protein 1 secretion (R  0.58, R  0.79, P  0.05),
suggesting that lower AT pO2 could drive AT inﬂammation in
obesity.
CONCLUSIONS—Adipose tissue rarefaction might lie upstream
of both low AT pO2 and inﬂammation in obesity. These results
suggest novel approaches to treat the dysfunctional AT found in
obesity. Diabetes 58:718–725, 2009
B
oth insulin resistance and -cell failure are
present in individuals with type 2 diabetes. In-
sulin resistance is closely linked to adiposity
with a central or visceral pattern, providing a
greater risk of insulin resistance and metabolic dysfunc-
tion. Adipose tissue (AT) serves as an endocrine organ
secreting a variety of autocrine, paracrine, and endocrine
factors that can produce or prevent insulin resistance (1).
The failure of AT to adequately proliferate and/or differ-
entiate to sequester lipids away from liver, skeletal mus-
cle, and the pancreatic -cell has been proposed as a
precursor to type 2 diabetes, broadening the number of
potential mechanisms linking obesity to insulin resistance
(2).
The increase in body fat in obesity should be accompa-
nied by an increase in vascularization, in order to provide
adequate oxygen and nutrients (3). In contrast to expec-
tations, obese mice have lower AT capillary density (rar-
efaction, also known as capillary drop out) and decreased
vascular endothelial growth factor (VEGF), the most po-
tent angiogenic factor (4,5). Consistent with this model,
preclinical studies suggest that obese AT is hypoxic (6);
however, the hypothesis that AT rarefaction might lead to
hypoxia remains untested.
In humans, short-term whole-body hypoxia decreases
insulin sensitivity (7) and short-term whole-body hyper-
oxygenation increases insulin sensitivity (8). In mice,
obesity is associated with lower oxygen partial pressure in
subcutaneous and visceral AT (6,9). Studies in postsurgi-
cal patients support the idea that AT oxygen partial
pressure (AT pO2) is lower in obesity (10).
In vitro hypoxic adipocytes secrete inﬂammatory mole-
cules such as tumor necrosis factor (TNF) , interleukin
(IL)1, IL6, macrophage inﬂammatory protein (MIP), and
plasminogen activator inhibitor-1 (6,11). Increased AT
inﬂammation is a feature of obesity and type 2 diabetes
(12). Hypoxic cells secrete chemokines, which attract
macrophages, presumably to clear out necrotic cells and
tissue (13). This suggests the hypothesis that the increase
in AT macrophage content seen in human obesity (12)
might be due to AT hypoxia.
These preclinical and cell culture experiments suggest
that hypoxia might play a role in the inﬂammation and
insulin resistance observed in human obesity. To test this
hypothesis, we measured subcutaneous abdominal AT
oxygenation (AT pO2) in lean and overweight/obese hu-
man subjects and related AT pO2 to the structure and
function of AT.
RESEARCH DESIGN AND METHODS
Twenty-one subjects were recruited and screened based on their BMI: lean
(20–25 kg/m
2) or overweight/obese (27–35 kg/m
2). Recruiting was conducted
via newsprint, postcards, and the Pennington Biomedical Research Center
(PBRC) webpage. Subjects were excluded if they had signiﬁcant renal,
cardiac, liver, lung, or neurological disease. Hypertension was acceptable if
blood pressure was 140/90 mmHg on medications. Subjects were excluded
for prior use of thiazolidinediones or injectable antihyperglycemic medica-
tion; drugs known to affect lipid metabolism, energy metabolism, or body
weight; alcohol or other drug abuse; and smoking. The protocol was approved
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718 DIABETES, VOL. 58, MARCH 2009by the institutional review board at the PBRC, and all volunteers gave written
informed consent.
Body composition was measured by dual-energy X-ray absorptiometry
(DEXA) on a Hologic Dual Energy X-ray Absorptiometer in the fan beam mode
(QDR 4500; Hologic, Waltham, MA). The coefﬁcient of variation for the
measurement of percentage of body fat is 1.7%. Two days prior and during an
in-patient stay, participants were fed a standardized diet (50% carbohydrate,
15% protein, and 35% fat). The number of calories to be provided (and
consumed) was calculated as 1.3  basal energy expenditure using Harris-
Benedict equation (665.10 	 [9.56  weight in kg] 	 [1.85  height in cm] –
[4.68  age in years for female and 66.47 	 {13.75  weight in kg} 	 {5.0 
height in cm}] – [6.76  age in years] for male subjects).
Measurement of subcutaneous abdominal AT pO2 and AT temperature.
AT pO2 was measured using a polarographic micro Clark-type electrode, and
AT temperature was measured using a thermocouple concomitantly during
two distinct procedures. The measurements were done with a single oxygen
probe (cat. no. C1), a single temperature probe (cat. no. C8), or a combined
oxygen and temperature probe (cat. no. CC1.P1; Integra Life Sciences,
Plainsboro, NJ). The probes were connected to an electronic unit (LICOX
CMP; brain oxygen-monitoring unit). This unit displays the AT temperature in
°C and the AT pO2 in mmHg (after controlling for the contribution of
temperature on AT pO2). After insertion, the system was allowed to equili-
brate for 30 min. Recording was stopped when the difference between
measurements done at 5-min interval was 1 mmHg (steady state); values
from the last 10 min were averaged (supplementary Fig. 3 [available in an
online appendix at http://dx.doi.org/10.2337/db08-1098). All measurements
were made supine, on the left side of the abdomen, at one-third the distance
between the umbilicus and the superior iliac crest (supplemental Fig. 1) and
with the skin uncovered at an ambient room temperature of 
25°C.
First, we measured AT pO2 (mmHg) with the probes inserted into a
gas-permeable silastic tubing implanted in the subdermal space as described
by Hopf (14) and optimized in our laboratory (indirect method, supplemental
Fig. 2). Second, AT pO2 was measured using a direct insertion method
developed by our laboratory (supplemental Fig. 2B). After cleaning the skin
with povidone-iodine solution and removal of the dried iodine with sterile
saline on gauze, a skin wheal was raised with 1% lidocaine. A combined
oxygen and temperature probe was inserted through a 3.2-cm-long 14-Ga IV
catheter (Medex) to a depth of 1 cm. The values obtained with the two
methods were highly correlated (R  0.64, P  0.01; n  13). However, the
second method was less invasive and provided less discomfort to the
volunteers. Therefore, after 13 subjects we only used the second method to
measure AT pO2 and AT temperature. All values in this manuscript are from
the “direct” measurement technique.
Euglycemic-hyperinsulinemic clamp. The clamp was performed as previ-
ously described (15). Brieﬂy, intravenous catheters were inserted in an
antecubital vein for infusions and in a vein on the dorsum of the contra-lateral
hand for sampling of arterialized blood. After baseline sampling, a primed-
continuous insulin infusion (80 mU/m
2 per min) was continued for 3–4 h.
Insulin was infused for at least 1 h after reaching a concentration of glucose

90 mg/dl. Plasma glucose was measured every 5 min and maintained by a
variable 20% glucose infusion. The mean rate of exogenous glucose infusion
during steady-state (last 30 min) was corrected for changes in glycemia and
divided by fat free mass to assess insulin sensitivity.
Laboratory measures. The following assays were done on blood drawn after
an overnight fast. Glucose was analyzed using a Beckman Coulter DXC 600
Pro (Brea, CA) and insulin via immunoassay on the Siemens Immulite 2000
(Siemens, Los Angeles, CA).
AT biopsy. The skin was anesthetized with a mixture of lidocaine (2%) and
bupivocaine (0.025%). AT was obtained using a blunt-ended needle designed
for liposuction (3- to 4-mm diameter “mercedes” liposuction needle; M.D.
Resource, Hayward, CA) and processed at the bedside by washing in 37°C PBS
and snap frozen or preserved in 10% formalin for parafﬁn blocking. The
biopsies obtained from the ﬁrst completed 14 subjects (8 female and 6 male
subjects) were used for the following procedures.
Short-term AT release of cytokines. As previously described (16), fresh AT
was collected into pregassed 37°C medium 199 and minced into 2- to 5-mg
fragments and washed over a nylon mesh. Aliquots were incubated for3hi n
medium 199 containing 1% BSA under a 95% O2 to 5% CO2 atmosphere in a
shaking water bath (60 cycles/min, 37°C).
MIP1 (chemokine [C-C motif] ligand 3), VEGF, TNF, leptin, IL1, and
monocyte chemotactic protein-1 were measured in the condition media using
the Luminex system (cat. no. HCYT060K03; MIllipore). The conditioned media
was assayed for lactate dehydrogenase and conﬁrmed the absence of cell
lysis. Of 14 subjects, 1 subject had no biopsy tissue for the assay (because of
technical limitations) and 1 subject had the assay compromised during
processing and therefore could not be used. Subsequently, cytokine release
was measured in 12 subjects (5 lean and 7 overweight/obese, from which 5
were male and 7 were female). Conditioned media concentrations of VEGF,
TNF, and leptin were below the detection level of the assay (data not
shown).
Capillary density. The tissue was cleaned in PBS, ﬁxed in 10% formalin, and
embedded in parafﬁn. Before staining, 3-m sections were deparafﬁnized and
dehydrated by incubation in Xylene (cat. no 247642; Sigma-Aldrich, MO) for 20
min followed by incubation with 100, 90, 80, 70, and 60% ethanol. Slides were
rinsed with PBS (20 min). The sections were incubated for 30 min in a dark
moist container with the staining solution containing lectin ﬂuorescein
isothiocyanate (FITC) conjugate (from Griffonia simplicifolia [GS]) 25 g/ml
(cat. no. L2895; Sigma-Aldrich), lectin tetramethylrhodamine isothiocyanate
conjugate (from Ulex europaeus [UAE]), 10 g/ml (cat. no. L4889; Sigma-
Aldrich), and 4,6-diamidino-2-phenylindole, dihydrochloride (DAPI) 0.3 
(cat. no. D9564; Sigma-Aldrich). The GS lectin stains the plasmalemma, UEA
stains the capillaries (17), and DAPI stains nuclei (18). In a preliminary
experiment, the AT sections were stained with DAPI in addition to GS lectin
and UEA lectin, showing that UEA lectin does not stain nuclei (supplemental
Fig. 4). The sections were rinsed with PBS (40 min) and then mounted on
microscope slides with a water-soluble mounting medium (cat. no. M7644-1;
Cardinal Health). Images of the stained sections were taken with a Zeiss
Axioplan 2 upright microscope (Intelligent Imaging Innovations) using Zeiss
Axioplan 2 with a Photometrics CoolSnap HQ CCD camera and a Sutter
Lambda LS 175W Xenon arc lamp. A planar Apochromat 20/0.75 objective
lens, three ﬁlter sets (DAPI-EX 360/40, FITC-EX HQ487/25, and CY3-EX
HQ535/50) and Slidebook Software version 2.0 were used for image capture.
Microvessels were counted using MBF ImageJ Bundle software. Microvessel
density was expressed as the number of microvessels per millimeter of
section area, averaged across 6–10 images acquired from each section.
Quantitative RT-PCR. Human total RNA from 
100 mg AT was isolated by
column puriﬁcation (Qiagen). All primers and probes were designed using
Primer Express version 2.1 (Applied Biosystems). Sequences of primers and
probes are shown in a supplementary table. Leptin and GLUT1 were from ABI
(cat. no. Hs00174877_m1, Hs00197884_m1). GLUT1 mRNA was not detectable
in the AT samples. Real-time quantitative RT-PCRs (qRT-PCRs) (19) were
performed as one-step reactions in ABI PRISM 7900 (Applied Biosystems)
using the following parameters: one cycle of 48°C for 30 min, then 95°C for 10
min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. The relative
standard curve method was used to calculate the quantity of the target gene
for each tissue extract with an internal control. The “housekeeping gene”
cyclophilin B was previously demonstrated to be “stable” across lean and
obese subjects (20–22). Therefore, each sample value was divided by the
quantity of cyclophilin B as previously described (20–23).
Adipocyte size. Mean adipocyte size was measured as previously described
(24). Tissue was ﬁxed in osmium tetroxide. Dissociation and digestion of
proteins was performed with 8 mol/l urea/NaCl. Cells were ﬁltered over a
10-m nylon screen then recollected in a Triton X-100 solution. Approximately
2,500 cells from each sample were analyzed on a Coulter Counter using a
400-m aperture.
Statistical methods. Comparison between the lean and overweight/obese
subjects was performed using an unpaired t test. Statistical signiﬁcance was
deﬁned relative to a nominal two-sided 5% type-1 error rate. Values are
presented as means  SD. All analyses were performed in JMP (version 5.0.1;
SAS, Cary, NC).
RESULTS
Subject characteristics. Subject characteristics are
listed in Table 1. The subjects were men (n  11) and
women (n  10) with diverse ethnicity: Caucasian (n 
10), African American (n  10), or Chinese (n  1). The
lean subjects were matched for age with the overweight/
obese subjects without diabetes; however, both goups
were younger than the overweight/obese subjects with
diabetes (P  0.05). Waist circumference was signiﬁcantly
larger in the overweight/obese versus lean group (P 
0.05). The range of BMI was 20.4–23.8 kg/m
2 in the lean
group and 28.9–34.7 kg/m
2 in the overweight/obese group.
By design, the overweight/obese group had greater BMI
compared with the lean group (P  0.05) and greater
percent fat (P  0.05). As expected, overweight/obese
subjects had lower insulin sensitivity, as shown by the
glucose disposal rates compared with lean subjects (P 
0.05).
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AT temperature without activation of hypoxia target
genes. We observed lower AT pO2 in overweight/obese
than lean subjects (range 29.1–62.8 vs. 40.5–73.8 mmHg;
P  0.05) (Fig. 1A; Table 1). In addition, AT pO2 was
negatively correlated with percent fat (R  0.50, P 
0.05) (Fig. 1B) and fat mass (R  0.48, P  0.05). AT
temperature was lower in overweight/obese than lean
subjects (P  0.05) (Table 1) and was negatively corre-
lated with percent body fat (R  0.62, P  0.01) (Fig. 1C)
Race, sex, and age were not signiﬁcant contributors to AT
pO2 or AT temperature (P  NS). There was no relation-
ship between the use of antihypertensive medication and
AT pO2 (P  NS).
The differences in AT pO2 cannot be explained by
differences in AT temperature. A 6°C difference in temper-
ature leads to a 1-mmHg difference in pO2 at atmospheric
pressure (suplemental Fig. 3B), a value that is trivial
compared with the range of values for AT pO2 (
35
mmHg). Next, we measured the expression of known
HIF-1 targets: pyruvate dehydrogenase kinase (PDK) 1 and
VEGF. We found that PDK1 and VEGF were not upregu-
lated in overweight/obese subjects (Table 2), suggesting
that the decrease in AT pO2 is not sufﬁcient to activate the
hypoxia pathway that would increase AT pO2 to normal
values.
Within the overweight/obese group, there were six over-
weight/obese subjects without type 2 diabetes and six
overweight/obese subjects with type 2 diabetes. The
groups had similar BMI and insulin sensitivity, and we
found similar AT pO2 and AT temperature. Data in humans
suggests that whole-body hypoxia might cause insulin
resistance (7,8); however, the relationship with AT pO2 has
not been explored. We found that AT pO2 did not correlate
with glucose disposal rate, a gold-standard measure of
skeletal muscle insulin resistance (R  0.21, P  NS).
Evidence for rarefaction in overweight/obese AT. AT
pO2 could be reduced via several potential mechanisms:
increased demand for oxygen, decreased blood ﬂow due
to vasoconstriction, or decreased blood ﬂow due to rar-
efaction. To explore the latter possibility, we measured
capillary density in AT samples collected from the contra
lateral abdomen. Capillary density in AT was reduced by
44% in overweight/obese subjects compared with lean
subjects (172  60 vs. 308  135, P  0.05) (Fig. 2C). We
found that VEGF mRNA was 58% lower in overweight/
obese versus lean subjects (P  0.05) (Fig. 2D). Capillary
density and VEGF expression were strongly correlated
(R  0.81, P  0.01) (Fig. 2E). AT pO2 was also positively
correlated with VEGF mRNA (R  0.54, P  0.05). Total
body fat (%) was negatively correlated with capillary
density (R  0.69, P  0.01) and VEGF mRNA (R 
0.78, P  0.01) (Fig. 2F). To determine the effect of sex,
we used capillary density as the dependent variable and
percent fat and sex as the independent variables. The
effect of sex on capillary density was not signiﬁcant (data
not shown).
Classically, peroxisome proliferator–activated receptor
(PPAR) is known as a nuclear hormone receptor that
increases adipogenesis and turns on lipogenesis (25).
However, recent evidence strongly suggests that PPAR
also drives angiogenesis (26–28). We found that PPAR1
was strongly correlated with VEGF (R  0.94, P  0.01)
(Fig. 2G) and capillary density (R  0.72, P  0.01).
Ultimately, PPAR1 was correlated with AT pO2 (R  0.60,
P  0.05).
Angiopoetin 1 (ANG1) is involved in vascular remodel-
ing and is negatively correlated with the rate of body
weight change in animals (4,29). We found that ANG1
negatively correlated with AT pO2 (R  0.57, P  0.05)
and positively with percent fat (R  0.73, P  0.05). These
suggest that overweight/obese subjects with lower AT pO2
have less vascular remodeling compared with lean sub-
jects. Overweight/obese subjects also had a 66% greater
expression of collagen VI (collagen VI 3 subunit [COL6]),
a extracellular matrix collagen (P  0.05, Table 2). Expres-
sion of COL6 was positively correlated with percent body
fat (R  0.55, P  0.05) and inversely correlated with AT
pO2 (R  0.81, P  0.01) Fig. 2H). In addition to
increased AT mass, overweight/obese subjects had greater
mean adipocyte size compared with lean subjects (0.86 
0.2 vs. 0.43  0.13 l, P  0.05). Mean adipocyte size was
negatively correlated with capillary density (R  0.66,
P  0.01) and VEGF (R  0.69, P  0.01).
AT pO2 and AT inﬂammation. Based on in vitro studies
in cultured adipocytes (6,11), we hypothesized that lower
AT pO2 might lead to macrophage recruitment and the
secretion of inﬂammatory cytokines. We have previously
validated the use of macrophage-associated antigen
[MAC2]/CD163 and CD68 as markers of AT macrophage
inﬁltration (R
2  0.77, P  0.001) (B. Kozak, J. Gimble, S.R.
Smith, unpublished data). Both MAC2/CD163 and CD68
were inversely correlated with AT pO2 (Fig. 3A and B; R 
0.66, P  0.05 and R  0.51, P  NS) consistent with
accumulation of macrophages in AT with reduced oxygen-
ation. Furthermore, MIP1 was higher in the overweight/
obese subjects (Table 2) and AT pO2 was inversely
correlated with MIP1 expression (R  0.41, P  NS)
(Fig. 3C) and MIP1 secretion in the media (R  0.79,
P  0.05) (Fig. 3D). There was a trend toward higher
monocyte chemotactic protein-1 and IL1 in obesity and
negative correlations with AT pO2, but these did not reach
statistical signiﬁcance. However, IL1 secretion was neg-
atively correlated with VEGF mRNA (R  0.70, P 
0.001) and capillary density (R  0.61, P  0.05).
TABLE 1
Clinical characteristics of the study population
Lean
subjects
Overweight/
obese
subjects P
Sex (male/female) 9 (5/4) 12 (6/6)
Age (years) 22.6  3.3 38.9  15.8 0.05
Weight (kg) 64.8  7.7 92.0  12.8 0.05
BMI (kg/m
2) 22.1  1.0 31.7  1.9 0.05
Waist (cm) 73  4.4 100  10.4 0.05
Percent fat (DEXA) 20.9  7.6 34.2  8.2 0.05
Fasting glucose (mg/dl) 89  3 110  27 0.05
Fasting insulin (U/ml) 4.9  2.0 14.4  9.6 0.05
Glucose disposal rate during
euglycemic-
hyperglycemic clamp
(mg/min  kg fat-free
mass) 11.2  3.4 6.0  2.2 0.05
Abdominal subcutaneous AT 0.05
AT pO2 (mmHg) 55.4  9.1 46.8  10.6 0.05
AT temperature (°C) 34.0  1.0 32.1  1.4 0.05
Data are means  SD. Percent body fat was measured by DEXA and
represents mass as the percent of total body weight. The lean group
included two African Americans, six Caucasians, and one Asian. The
overweight/obese group included eight African Americans and four
Caucasians. *P 0.05.
ADIPOSE TISSUE OXYGENATION IN HUMAN OBESITY
720 DIABETES, VOL. 58, MARCH 2009DISCUSSION
Trayhurn and Wood (30) ﬁrst hypothesized that hypoxia of
AT might play a role in insulin resistance. This hypothesis
was based on experiments demonstrating that surrogate
markers of hypoxia were increased in the AT of obese
animals (30). We found that reduced AT pO2 in over-
weight/obese subjects and AT pO2 strongly correlates with
percent body fat. We also found a signiﬁcant reduction in
AT temperature in overweight/obese subjects and a strong
inverse correlation with percent total fat. This is in accor-
dance with previous ﬁndings (31) showing a lower skin
temperature in obesity. The presence of capillary rarefac-
tion suggests that decreased AT perfusion might also play
a role. Indeed, there is evidence to suggest that obese
subjects have lower blood ﬂow in abdominal adipose
subcutaneous tissue (32). Further work using direct mea-
sures of both AT pO2 and direct measures of AT blood ﬂow
such as xenon washout are needed to formally address
this hypothesis. There is additional evidence that obese
mice have decreased oxygenation in epididymal and ret-
roperitoneal AT (6,9) and that weight loss increases oxy-
genation (6). Choban et al. (33) observed an increased
incidence of postsurgical wound infections in obese pa-
tients. This same group, measuring AT pO2 in the upper
arm, subsequently showed that decreased oxygenation of
AT contributes to the increased risk of infection (34). AT
mass and adipocyte hypertrophy are closely related to the
metabolic complications of obesity (35). In vivo data
suggested a role for hypoxia in insulin resistance even
though AT pO2 has never been measured in human sub-
jects (7,8). We were unable to demonstrate a correlation
between insulin sensitivity and AT pO2. A lack of correla-
tion of AT pO2 and insulin sensitivity may be due to lack of
power because this AT pO2 and inﬂammation are just two
of many factors that induce insulin resistance or perhaps
because there is simply no meaningful biological relation-
ship. The correlation between macrophage content and
insulin resistance is modest (36). One limitation of our
study is that only one region of the body was measured
and only at one depth.
Most hypoxic tissues develop strong transcriptional,
metabolic, and secretory responses to reduced oxygen-
ation in order to increase capillary density and to correct
the hypoxia. Hypoxia turns on genes that act to increase
oxygen availability by decreasing oxygen consumption
(switching “on” anaerobic glycolysis) and stimulating an-
giogenesis. Hypoxia target genes expressed in AT include
PDK1 and VEGF (37). Consistent with this data, VEGF and
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FIG. 1. AT pO2 and AT temperature are inversely correlated with percent body fat. AT pO2, measured by direct insertion of a micro Clark-type
electrode into abdominal subcutaneous AT, was lower in overweight/obese group (O/O) compared with lean subjects (A) and inversely correlated
with percent body fat (B). AT temperature measured by a thermocouple inserted into the abdominal AT was inversely correlated with percent
body fat (C). Males are represented by squares and females by circles, ﬁlled with different colors as follows: white for lean, gray for O/O without
type 2 diabetes, and black for O/O with type 2 diabetes.
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(a hypoxic environment) (6,9,11). In contrast to our ex-
pectations, we found that lower AT pO2 in overweight/
obese subjects did not induce an increase in hypoxia
targets (PDK1, VEGF). Also, capillary density and VEGF
were decreased in overweight/obese AT along with a
lower AT pO2. This suggests that the transcriptional coun-
terregulatory system was not activated. One should note,
however, that the lowest value of AT pO2 in the over-
weight/obese group was 29 mmHg; this corresponds to
3.8% oxygen compared with the 1% oxygen used in the cell
culture experiments. This suggests that overweight/obese
subjects have low AT pO2 but not low enough to mount a
counterregulatory response driven during a response to
hypoxia. Consistent to our results, Lijnen et al. (5) found
that obese mice have both lower VEGF and lower vascular
density in AT. In addition, it is known that spleen, thymus,
and retina have low pO2 in normal rats (38), suggesting
that angiogenesis is activated at different levels of oxygen-
ation for different types of tissue or that oxygenation could
inﬂuence angiogenesis. One limitation of our study is that
we did not measure VEGF protein, and this should be
addressed in future experiments.
Recent data suggests that PPAR1 might be required for
angiogenesis in AT (39). PPAR drives VEGF (and angio-
genesis) (26–28). We found a strong positive correlation
between PPAR1 and VEGF and between VEGF and AT
pO2. One way to interpret this data is that PPAR1 drives
angiogenesis in human AT and therefore is a key controller
of AT pO2. More work is needed to test this hypothesis.
AT expansion (adipogenesis) during development is
preceded by a wave of neovascularization (40). Vascular
plasticity may play a role in the ability of AT to increase or
decrease in size (29,41). Our data suggests that reduced
capillary density might restrict the growth of AT. Our
ﬁnding of reduced capillary density in subcutaneous AT in
obesity suggests the hypothesis that the failure of the
vasculature to expand with increasing subcutaneous obe-
sity might limit adipogenesis in subcutaneous depot. If
visceral AT were not similarly restricted, this might allow
for the growth of visceral AT. Further work measuring AT
pO2 and capillary density in omental and mesenteric AT is
needed to test this hypothesis.
Previous studies have shown that COL6 is abundantly
expressed by adipocytes (42), and obese mice have in-
creased COL6 expression in the extracellular matrix (43).
We found that overweight/obese subjects with low AT pO2
have greater expression of COL6, and COL6 expression
increased with increased body fat and fat-cell size. Scherer
et al. (44) suggests that proteolytic fragments of COL6
promote tumor growth through prosurvival and prolifera-
tion signaling pathways such as Akt and -catenin. This
suggests that new blood vessel formation is restricted by
increased extracellular matrix or that a reduction in
angiogenesis leads to increases in the formation of the
extracellular matrix as exempliﬁed by COL6. Further work
is needed to separate these two possibilities.
AT inﬂammation has received much attention as an
important factor in insulin resistance and type 2 diabetes
(6,12,45). Previous in vitro and in vivo preclinical studies
showed that hypoxia induces inﬂammation that might
contribute to insulin resistance (6,11). We found that in
humans, AT pO2 correlates with macrophage markers
(CD68 and MAC2/CD163). In addition, AT secretion of
MIP1, a potent macrophage chemokine (46,47), in-
creased as AT pO2 decreased. This is consistent with
recent data showing upregulation of MIP1 in obesity (48).
This is supportive of the hypothesis that lower oxygen-
ation drives inﬂammation by upregulating adipocyte che-
mokine secretion but, as discussed previously, not by
activating the classic hypoxia pathway and VEGF. How-
ever, it is possible that inﬂammation could drive hypoxia.
Given that MIP1 has been implicated in angiogenesis, it is
unclear why MIP1 is up when capillary density is down.
Further work is needed to understand the factors regulat-
ing angiogenesis in human AT.
In summary, we provide direct evidence of lower AT
pO2 in overweight/obese subjects and that the most likely
causes are decreased capillary density and reduced ex-
pression of the angiogenic factors like VEGF and PPAR1
and increased expression of COL6. This suggests that low
AT pO2 in overweight/obese subjects does not result in a
TABLE 2
AT characteristics of lean versus overweight/obese volunteers
Lean Overweight/obese P
Correlation with
percent fat
rP
n 68
Gene expression (AU)
Leptin mRNA 0.19  0.11 0.57  0.12 0.05 0.74 0.05
PDK1 mRNA 0.63  0.24 0.45  0.21 0.05 0.10
VEGF mRNA 2.46  1.11 1.04  0.34 0.05 0.78 0.05
ANG1 mRNA 0.41  0.13 0.69  0.11 0.05 0.73 0.05
PPAR1 mRNA 1.33  0.36 0.74  0.21 0.05 0.73 0.05
COL6 mRNA 0.32  0.17 0.53  0.16 0.05 0.55 0.05
CD68 antigen mRNA 0.23  0.05 0.62  0.27 0.05 0.64 0.05
MAC2/CD163 mRNA 0.56  0.22 1.49  0.63 0.05 0.72 0.05
MIP1 mRNA 0.02  0.01 0.21  0.18 0.05 0.60 0.05
MCP1 mRNA 0.12  0.05 0.25  0.11 0.05 0.43
Cytokine release (pg/mg tissue  h) 0.05
MIP1 0.44  0.38 0.96  0.69 0.05 0.60 0.05
MCP1 2.26  0.83 2.36  1.18 0.05 0.12
IL1 0.09  0.08 0.20  0.07 0.05 0.67 0.05
Data are means  SD. MCP1, macrophage chemoattractant protein 1.
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FIG. 2. Vascularization of AT. Representative AT sections from lean (A) and O/O (B) subjects stained with UEA lectin (orange) to label capillaries and with
GS lectin (green) to label the adipocyte plasmalemma. Capillary density (C) was measured and averaged across 6–10 histological sections for each subject
and VEGF mRNA expression measured by quantitative RT-PCR (D); both were lower in O/O versus lean subjects. VEGF mRNA was positively correlated with
capillary density (E) and PPAR1 mRNA (G) and inversely with percent body fat (F). H: Collagen VI (COL6) mRNA was negatively correlated with AT pO2.
Males are represented by squares and females by circles, ﬁlled with different colors as follows: white for lean, gray for O/O without type 2 diabetes, and black
for O/O with type 2 diabetes. (Please see http://dx.doi.org/10.2337/db08-1098 for a high-quality digital representation of this ﬁgure.)
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and that neovascularization is not activated. Decreased AT
pO2 was paralleled by an increase in the expression and
secretion of the chemokine and markers of macrophage
inﬁltration. These data suggests that proangiogenic thera-
pies might reduce AT inﬂammation, improve insulin ac-
tion, and reduce cardiovascular disease risk in obesity and
type 2 diabetes.
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